EBIT (Quarterly)

EBIT: Income before interest and taxes.

ADC Therapeutics SA (ADCT) had EBIT of $-44.15M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$18.84M
Net Income	$-56.65M
Cost of Goods Sold	$0.84M
Gross Profit	$18.00M
Operating Expenses	$62.99M
Operating Income	$-44.15M
Non-Operating Income/Expense	$-11.24M
Pre-Tax Income	$-55.39M
Normalized Pre-Tax Income	$-55.39M
Income after Taxes	$-56.65M
Income from Continuous Operations	$-56.65M
Consolidated Net Income/Loss	$-56.65M
Normalized Income after Taxes	$-56.65M
EBIT	$-44.15M
EBITDA	$-43.31M
Weighted-Average Shares Outstanding (Basic)	113.74M
Weighted-Average Shares Outstanding (Diluted)	113.74M
Earnings per Share (EPS) (Basic)	$-0.50
Earnings per Share (EPS) (Diluted)	$-0.50
Balance Sheet Financials
Current Assets	$318.75M
Property, Plant, and Equipment	$0.00M
Long-Term Assets	$2.81M
Total Assets	$321.56M
Current Liabilities	$64.60M
Long-Term Debt	$114.47M
Long-Term Liabilities	$456.14M
Total Liabilities	$520.75M
Common Equity	$-199.18M
Tangible Shareholders Equity	$-199.18M
Shareholders Equity	$-199.18M
Common Shares Outstanding	112.50M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-80.42M
Cash Flow from Investing Activities	$-0.26M
Cash Flow from Financial Activities	$94.05M
Beginning Cash	$250.87M
End Cash	$264.56M
Increase/Decrease in Cash	$13.69M
Stock-Based Compensation	$4.23M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.93
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-1.35
Debt to Equity Ratio	-0.57
Gross Margin	95.56%
Operating Margin	-234.34%
EBIT Margin	-234.34%
EBITDA Margin	--
Pre-Tax Profit Margin	-294.03%
Profit Margin	-300.68%
Free Cash Flow	$-80.69M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.06
Inventory Turnover	0.05
Receiveable Turnover	0.72
Days Sales in Receivables	125.09
Return on Equity	28.44%
Return on Tangible Equity	28.44%
Return on Assets	-17.62%
Return on Investments	66.87%
Book Value Per Share	$-1.77
Free Cash Flow per Share	$-0.71
Operating Cash Flow per Share	$-0.71

Data from Zacks Investment Research, Inc.